相关实验视频
Updated: May 5, 2026

12:19
Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
Published on: October 7, 2009
27.7K
脂蛋白在一个"转折点":该案将转向通用查
1Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.
American journal of preventive cardiology
|September 8, 2025
概括
建议对升高脂蛋白[Lp[a]进行普遍查,这是动脉样硬化心血管疾病 (ASCVD) 的关键遗传风险因素. 一个单一的Lp (a) 测试可以指导积极的风险管理,并确定新兴疗法的候选者.
科学领域:
- 心脏病学 心脏病学
- 遗传学 是一个遗传学.
- 预防医学 预防医学
背景情况:
- 升高的脂蛋白[Lp[a]是动脉样硬化心血管疾病 (ASCVD) 的重要,基因决定的风险因素.
- 尽管Lp (a) 已具备既定作用,但在临床实践中尚未得到认可和测试.
- 当前的理解强调了需要提高认识和系统查的必要性.
研究的目的:
- 倡导对脂蛋白水平进行普遍查.
- 强调LP测试在风险评估和管理中的临床实用性.
- 审查当前和未来的治疗策略来管理升高的Lp.
主要方法:
- 对Lp (a) 作为心血管风险因素的现有证据的审查.
- 一次性,终身Lp (a) 查测试的好处分析.
- 讨论临床管理策略和新疗法.
主要成果:
- Lp(a) 水平>90%是基因决定的,并且随着时间的推移相对稳定.
- 升高的Lp (a) 需要更积极的风险因素修改,包括降低LDL-C和考虑PCSK9抑制剂.
- Lp (a) 测试有助于分级查,并确定用于新疗法的临床试验的个体.
结论:
- 全球Lp(a) 查是一种高收益的策略,用于识别心血管风险增加的个体.
- 早期识别可以实现个性化风险管理和及时干预.
- 新兴的Lp (a) 降低疗法为减少残留心血管风险提供了未来的希望.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
973
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
973
Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Coronary Artery Disease IV: Preventive Measures
890
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741

